| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Impairment of long-lived assets | NaN | NaN | 0 | 0 |
| Change in fair value of contingent considerations and holdbacks | NaN | NaN | 0 | NaN |
| Gain on sale of business | NaN | NaN | 0 | 48,847 |
| Net loss | -44,021 | -30,507 | -27,138 | -50,532 |
| Non-cash lease expense, net of tenant improvement allowance | NaN | NaN | -20 | NaN |
| Depreciation and amortization | 6,414 | 6,194 | 6,004 | 18,849 |
| Stock-based compensation expense | 18,936 | 13,273 | 16,083 | 48,376 |
| Accrued expenses | NaN | 1,509 | 2,317 | 3,434 |
| Other non-cash adjustments | 498 | 336 | -240 | -1,963 |
| Accounts receivable, net | 14,238 | -6,826 | 7,210 | 15,172 |
| Inventories | 590 | 4,615 | 2,368 | 1,861 |
| Prepaid expenses and other current assets | 11,126 | 7,735 | 1,895 | 1,822 |
| Other liabilities | NaN | 1,316 | 1,135 | 5,477 |
| Other non-current assets | 641 | -225 | 965 | 603 |
| Accounts payable | 69 | 1,472 | -284 | 9,616 |
| Accrued compensation | 8,168 | -12,436 | 2,287 | -4,692 |
| Accrued and other liabilities | 22,793 | NaN | NaN | NaN |
| Proceeds from sale of business | NaN | NaN | 0 | 2,500 |
| Net cash used in operating activities | -17,559 | -24,814 | -11,814 | -35,814 |
| Purchases of property and equipment | 7,887 | 9,974 | 12,427 | 15,577 |
| Purchase of intangible asset | 100 | NaN | NaN | NaN |
| Purchases of investments | 4,718 | 20,509 | 21,136 | 28,257 |
| Proceeds from maturity of investments | 5,000 | 20,550 | 21,160 | 28,975 |
| Cash paid for asset acquisition | 5,000 | NaN | NaN | NaN |
| Cash paid for investment in equity securities | 1 | NaN | NaN | NaN |
| Net cash used in investing activities | -12,706 | -9,933 | -12,403 | -12,359 |
| Proceeds from exercise of stock options | 1,789 | 300 | 3,792 | 5,551 |
| Proceeds from the issuance of liability related to sale of future revenue | 0 | 0 | 0 | 15,000 |
| Proceeds from issuance under employee stock purchase plan | 2,357 | NaN | 1,784 | 2,429 |
| Repurchases of common stock for income tax withholding | 8 | 2 | 2 | 14 |
| Net cash provided by financing activities | 4,138 | 298 | 5,574 | 22,966 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -6 | 9 | 163 | -20 |
| Net decrease in cash, cash equivalents, and restricted cash | -26,133 | -34,440 | -18,480 | -25,227 |
| Cash, cash equivalents, and restricted cash at beginning of period | 150,985 | 185,425 | 229,132 | NaN |
| Cash, cash equivalents, and restricted cash at end of period | 124,852 | 150,985 | 185,425 | NaN |
Twist Bioscience Corp (TWST)
Twist Bioscience Corp (TWST)